In contrast to most hormonal biomarkers of the follicular status, anti-Müllerian hormone (AMH) is exclusively produced by the granulosa cells of a wide range of follicles (primary to the early antral stages), presumably FSH-independently and with little susceptibility to disorders of antral follicle growth during the luteal-follicular transition. This paper summarizes the authors' clinical rese...

BACKGROUND Anti-Mullerian hormone (AMH), which is secreted by preantral and small antral follicles, has been found to be a valuable marker of ovarian reserve. The purpose of this study was to determine age-related changes in AMH levels that occur in Taiwanese women and to determine whether measuring AMH is a highly sensitive and specific tool for diagnosing polycystic ovarian syndrome (PCOS) in...

The role of Anti-Müllerian hormone (Amh) during gonad development has been studied extensively in mammals, but is less well understood in other vertebrates. In male mammalian embryos, Sox9 activates expression of Amh, which initiates the regression of the Mullerian ducts and inhibits the expression of aromatase (Cyp19a1), the enzyme that converts androgens to estrogens. To better understand sha...

BACKGROUND The number of unintentionally childless couples is increasing as more couples seek to conceive for the first time in the third or fourth decade of the woman's life. Determination of ovarian reserve is an essential component of infertility assessment. The Anti-Müllerian-Hormone (AMH) seems to be the most reliable predictor of ovarian reserve. In this study we analyzed AMH in a cohort ...

BACKGROUND The ideal test for ovarian reserve should permit the identification of women who have no real chance of pregnancy with IVF treatments consequent upon an extremely reduced ovarian reserve. The aim of the current study was to evaluate pregnancy rates in patients with low AMH levels (0.2-1 ng/ml) and extremely low AMH levels (<0.2 ng/ml) and to determine the cumulative pregnancy rates f...

background: evaluation of anti-mullerian hormone (amh) cut-off levels in assisted reproductive technology (art) as predictive factor for individualization of stimulation protocols and to avoid ovarian hyperstimulation syndrome (ohss). materials and methods: in a retrospective study, 177 infertile patients were assessed for amh in serum and follicular fluid (ff) on the day of follicular puncture...

BACKGROUND Follicle stimulating hormone (FSH) and anti-Müllerian hormone (AMH) represent the two most frequently utilized laboratory tests in determining ovarian reserve (OR). This study determined the clinical significance of their concordance and discordance in female infertility patients. METHODS We investigated 366 consecutive infertility patients (350 reached IVF), excluding women with p...

OBJECTIVE To assess the variability of antimüllerian hormone (AMH) concentrations in women with "adequate ovarian reserve" during unstimulated menstrual cycles and to determine the impact on clinical classifications. DESIGN Pilot cohort study. SETTING Private fertility clinic. PATIENT(S) Twelve consecutive women (aged 29 to 43 years) referred to a fertility service, with AMH measurements ...

Anti-Mullerian hormone (AMH) is a protein that inhibits the development of the mullerian ducts (paramesonephric ducts) in the male embryo. AMH prevents the development of the mullerian ducts into the uterus and other mullerian structures in the first 8 weeks of gestational age. AMH is produced by granulosa cells of the ovary during the reproductive years and controls the formation of primary fo...

BACKGROUND AND AIM OF THE STUDY Serum anti-Müllerian hormone (AMH) is a reliable marker of ovarian reserve, and it has been shown to be correlated with reproductive outcomes in grouped analyses. However, practical data is scarce for the physician and the patients to predict these outcomes in an individual couple according to serum AMH measured prior to assisted reproduction technology (ART) pro...